Lawsuit for Investors in shares of Akorn, Inc. (NASDAQ: AKRX) announced by Shareholders Foundation
SAN DIEGO, June 04, 2018 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Akorn, Inc. (NASDAQ: AKRX) shares.
Investors who purchased shares of Akorn, Inc. (NASDAQ:AKRX) in March 2017 or earlier and continue to hold NASDAQ: AKRX shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On March 8, 2018, a lawsuit was filed against Akorn, Inc. over alleged securities laws violations. The plaintiff claims that the defendants made materially false and/or misleading statements and/or failed to disclose that: Akorn’s failure to comply with FDA data integrity requirements would jeopardize Fresenius’s acquisition of Akorn, that Akorn lacked effective internal controls over financial reporting, and that as a result, Akorn’s financial statements were materially false and misleading at all relevant times.
Those who purchased Akorn, Inc. (NASDAQ:AKRX) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
